Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries

Published:2018-11-12 Issue:1 Volume:28 Page:123-143
ISSN:1057-9230
Container-title:Health Economics
language:en
Short-container-title:Health Economics

Author:

Barrenho Eliana¹²³^ORCID,Miraldo Marisa¹²³^ORCID,Smith Peter C.¹³^ORCID

Affiliation:

1. Imperial College Business School Department of Management; Imperial College London; London UK

2. Centre for Health Economics & Policy Innovation; Imperial College Business School, Imperial College London; London UK

3. Hospinnomics; Paris School of Economics; France

Funder

Fundação para a Ciência e a Tecnologia, Ministério para a Educação e Ciência (FCT), Governo da República Portuguesa

Publisher

Wiley

Subject

Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hec.3833/fullpdf

Reference40 articles.

1. Does the development of new medicinal products in the European Union address global and regional health concerns?;Catalá-López;Population Health Metrics,2010

2. Burden of disease and economic evaluation of healthcare interventions: Are we investigating what really matters?;Catalá-López;BMC Health Services Research,2011

3. Fostering innovation and discovery in biomedical research;Cech;JAMA,2005

4. Centre for Diseases Control and Prevention 2011 Neglected tropical diseases http://www.cdc.gov/globalhealth/ntd/diseases/index.html

5. On the measurement of relative and absolute income-related health inequality;Clarke;Social Science & Medicine,2002

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Challenges to Solution: The Evolving Landscape of Leprosy Management;Advanced Therapeutics;2024-08-24

2. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis;BMJ Open;2024-03

3. The role of patient organisations in research and development: Evidence from rare diseases;Social Science & Medicine;2023-12

4. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019;2023-06-04

5. A note on disease burden and pharmaceutical R&D;Australian Economic Papers;2023-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3